These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 8605026

  • 21. Glycans and proteoglycans are involved in the interactions of human immunodeficiency virus type 1 envelope glycoprotein and of SDF-1alpha with membrane ligands of CD4(+) CXCR4(+) cells.
    Mbemba E, Benjouad A, Saffar L, Gattegno L.
    Virology; 1999 Dec 20; 265(2):354-64. PubMed ID: 10600606
    [Abstract] [Full Text] [Related]

  • 22. Binding of soluble recombinant HIV envelope glycoprotein, rgp120, induces conformational changes in the cellular membrane-anchored CD4 molecule.
    Yachou A, Sékaly RP.
    Biochem Biophys Res Commun; 1999 Nov 19; 265(2):428-33. PubMed ID: 10558884
    [Abstract] [Full Text] [Related]

  • 23. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
    Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J.
    Nature; 1996 Nov 14; 384(6605):179-83. PubMed ID: 8906795
    [Abstract] [Full Text] [Related]

  • 24. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.
    Murakami T, Zhang TY, Koyanagi Y, Tanaka Y, Kim J, Suzuki Y, Minoguchi S, Tamamura H, Waki M, Matsumoto A, Fujii N, Shida H, Hoxie JA, Peiper SC, Yamamoto N.
    J Virol; 1999 Sep 14; 73(9):7489-96. PubMed ID: 10438838
    [Abstract] [Full Text] [Related]

  • 25. Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II).
    Tamamura H, Arakaki R, Funakoshi H, Imai M, Otaka A, Ibuka T, Nakashima H, Murakami T, Waki M, Matsumoto A, Yamamoto N, Fujii N.
    Bioorg Med Chem; 1998 Feb 14; 6(2):231-8. PubMed ID: 9547946
    [Abstract] [Full Text] [Related]

  • 26. Lymphocytes and promonocytes attach to the synthetic [Tyr5,12, Lys7]- polyphemusin II peptide.
    Weeks BS, Nomizu M, Otaka A, Weston CA, Okusu A, Tamamura H, Matsumoto A, Yamamoto N, Fujii N.
    Biochem Biophys Res Commun; 1994 Jul 15; 202(1):470-5. PubMed ID: 8037749
    [Abstract] [Full Text] [Related]

  • 27. Structure-activity relationships of an anti-HIV peptide, T22.
    Tamamura H, Murakami T, Masuda M, Otaka A, Takada W, Ibuka T, Nakashima H, Waki M, Matsumoto A, Yamamoto N.
    Biochem Biophys Res Commun; 1994 Dec 30; 205(3):1729-35. PubMed ID: 7811258
    [Abstract] [Full Text] [Related]

  • 28. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.
    Tamamura H, Imai M, Ishihara T, Masuda M, Funakoshi H, Oyake H, Murakami T, Arakaki R, Nakashima H, Otaka A, Ibuka T, Waki M, Matsumoto A, Yamamoto N, Fujii N.
    Bioorg Med Chem; 1998 Jul 30; 6(7):1033-41. PubMed ID: 9730240
    [Abstract] [Full Text] [Related]

  • 29. Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure.
    Tamamura H, Waki M, Imai M, Otaka A, Ibuka T, Waki K, Miyamoto K, Matsumoto A, Murakami T, Nakashima H, Yamamoto N, Fujii N.
    Bioorg Med Chem; 1998 Apr 30; 6(4):473-9. PubMed ID: 9597190
    [Abstract] [Full Text] [Related]

  • 30. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II).
    Masuda M, Nakashima H, Ueda T, Naba H, Ikoma R, Otaka A, Terakawa Y, Tamamura H, Ibuka T, Murakami T.
    Biochem Biophys Res Commun; 1992 Dec 15; 189(2):845-50. PubMed ID: 1472056
    [Abstract] [Full Text] [Related]

  • 31. [A synthetic peptide "T22" as anti-HIV agents].
    Nakashima H, Murakami T.
    Nihon Rinsho; 1993 Sep 15; 51 Suppl():146-52. PubMed ID: 8271378
    [No Abstract] [Full Text] [Related]

  • 32. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion.
    Nakashima H, Masuda M, Murakami T, Koyanagi Y, Matsumoto A, Fujii N, Yamamoto N.
    Antimicrob Agents Chemother; 1992 Jun 15; 36(6):1249-55. PubMed ID: 1384424
    [Abstract] [Full Text] [Related]

  • 33. A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance.
    Tamamura H, Kuroda M, Masuda M, Otaka A, Funakoshi S, Nakashima H, Yamamoto N, Waki M, Matsumoto A, Lancelin JM.
    Biochim Biophys Acta; 1993 May 13; 1163(2):209-16. PubMed ID: 8490053
    [Abstract] [Full Text] [Related]

  • 34. Novel therapies based on mechanisms of HIV-1 cell entry.
    Kilby JM, Eron JJ.
    N Engl J Med; 2003 May 29; 348(22):2228-38. PubMed ID: 12773651
    [No Abstract] [Full Text] [Related]

  • 35. Pharmacophore determination of a gp120 C terminal-derived anti-HIV peptide construct interfering with membrane fusion suggesting that processing of the gp120 C terminus is a prelude to fusion.
    Barbouche R, Feyfant E, Belhaj B, Fenouillet E.
    AIDS Res Hum Retroviruses; 2002 Feb 10; 18(3):201-6. PubMed ID: 11839154
    [Abstract] [Full Text] [Related]

  • 36. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection.
    Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N, Nagasawa T.
    J Exp Med; 1997 Oct 20; 186(8):1389-93. PubMed ID: 9334379
    [Abstract] [Full Text] [Related]

  • 37. A heparin which binds to the envelope glycoprotein gp120 inhibits human immunodeficiency virus replication.
    Cardin AD, Taylor DL, Krstenansky JL, Tyms AS, Jackson RL.
    Trans Assoc Am Physicians; 1989 Oct 20; 102():101-9. PubMed ID: 2561637
    [No Abstract] [Full Text] [Related]

  • 38. [The antiviral action of recombinant forms of the human T-lymphocyte CD4 receptor].
    Zverev VV, Maliushova VV, Sidorov AV, Pugach AV, Shukhmina NR, Pille ER, Mel'nikova NL, Andzhaparidze OG.
    Vopr Virusol; 1994 Oct 20; 39(2):56-9. PubMed ID: 7517083
    [Abstract] [Full Text] [Related]

  • 39. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
    Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaka A, Ibuka T, Yamamoto N, Nakashima H, Fujii N.
    Biochem Biophys Res Commun; 1998 Dec 30; 253(3):877-82. PubMed ID: 9918823
    [Abstract] [Full Text] [Related]

  • 40. [Naphthalenedisulfonic acid (NDS) derivatives as anti-HIV agents].
    Baba M, Shigeta S.
    Nihon Rinsho; 1993 Sep 30; 51 Suppl():153-7. PubMed ID: 8271379
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.